All In Biotech

NDA 021620 · Reckitt Benckiser

Mucinex Dm

Dextromethorphan Hydrobromide, Guaifenesin · Oral · Expectorant

Last checked: Nov 20, 2026Latest source record: Aug 6, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Apr 29, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

206

29 Phase 3, 17 recruiting

FAERS reports

7,254

1,813 serious, 92 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 30, 2026.

Uses helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive temporarily relieves: cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants the intensity of coughing the impulse to cough to help you get to sleep

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 29, 2004 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLabelLetter
2 products under this application
  • MUCINEX DM · DEXTROMETHORPHAN HYDROBROMIDE 60MG; GUAIFENESIN 1.2GM · TABLET, EXTENDED RELEASE, ORAL · Over-the-counter
  • MUCINEX DM · DEXTROMETHORPHAN HYDROBROMIDE 30MG; GUAIFENESIN 600MG · TABLET, EXTENDED RELEASE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Dextromethorphan Hydrobromide" as an intervention, any sponsor and status, largest first.

All 206 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective988
  • dizziness861
  • diarrhoea636
  • accidental overdose542
  • nausea509
  • overdose389
  • product use in unapproved indication355
  • somnolence299
  • feeling abnormal288
  • headache287
  • vomiting286
  • dyspnoea278

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20052
20066
200721
200820
200977
2010138
2011126
2012110
2013140
2014123
2015202
2016608
2017774
2018733
2019658
2020491
2021239
2022458
2023650
2024737
2025591
2026349

Recalls

1 FDA enforcement reports for this application.

  • Nov 10, 2014 · Class III · Terminated

    Defective container: A customer complaint revealed the presence of a defective seal on the top of a Mucinex pouch

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 28 on PubMed

Sponsor: Reckitt Benckiser

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.